RECRUITING

Carnosine for Peripheral Arterial Disease Patients

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Oral supplementation of L-carnosine will increase muscle carnosine, stabilize HIF1-alpha promote angiogenesis, and thus improve the functioning of lower extremities in PAD patients.

Official Title

Carnosine for Peripheral Arterial Disease Patients (Car-PAD)

Quick Facts

Study Start:2023-03-01

Study Completion:2024-12-30

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05371145

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years to 80 Years

Sexes Eligible for Study:MALE

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Male subjects more than \>50 to \<80 years of age. 2. White or African American race. 3. English Speaking. 4. ABI 0.4-\< 0.60 5. Willing to comply with protocol requirements. 6. Able to provide informed consent. -	1. Subjects with HIV, hepatitis, significant liver disease, active infection, anemia, organ transplant, renal disease requiring dialysis, lung disease requiring oxygen, significant congenital heart disease, cancer of any type, and untreated thyroid disease. 2. Diagnosis of carnosinemia. 3. Known allergy to L-carnosine or meat. 4. Presence of a pacemaker. 5. Obesity from a known genetic defect. 6. Dementia. 7. Critical limb ischemia with below or above knee amputations. 8. Foot ulcers. 9. Major amputations. 10. Participating in other clinical trials. 11. End stage renal disease. 12. Presence of significant injury within 30 days before enrollment. 13. Prisoners. 14. Any metallic implants. 15. Poorly controlled diabetes (HbA1C \>9%) -

Inclusion Criteria

Exclusion Criteria

1. Male subjects more than \>50 to \<80 years of age.
2. White or African American race.
3. English Speaking.
4. ABI 0.4-\< 0.60
5. Willing to comply with protocol requirements.
6. Able to provide informed consent. -

1. Subjects with HIV, hepatitis, significant liver disease, active infection, anemia, organ transplant, renal disease requiring dialysis, lung disease requiring oxygen, significant congenital heart disease, cancer of any type, and untreated thyroid disease.
2. Diagnosis of carnosinemia.
3. Known allergy to L-carnosine or meat.
4. Presence of a pacemaker.
5. Obesity from a known genetic defect.
6. Dementia.
7. Critical limb ischemia with below or above knee amputations.
8. Foot ulcers.
9. Major amputations.
10. Participating in other clinical trials.
11. End stage renal disease.
12. Presence of significant injury within 30 days before enrollment.
13. Prisoners.
14. Any metallic implants.
15. Poorly controlled diabetes (HbA1C \>9%) -

Contacts and Locations

Study Locations (Sites)

University of Louisville

Louisville, Kentucky, 40202

United States

Collaborators and Investigators

Sponsor: Shahid Baba

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-01

Study Completion Date2024-12-30

Study Record Updates

Study Start Date2023-03-01

Study Completion Date2024-12-30

Terms related to this study

Additional Relevant MeSH Terms

Peripheral Arterial Disease